{
    "clinical_study": {
        "@rank": "55163", 
        "acronym": "FANCY", 
        "arm_group": [
            {
                "arm_group_label": "standard saline infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "standard  i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure."
            }, 
            {
                "arm_group_label": "fenoldopam infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "combination of  i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure."
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury\n      (AKI) when they undergo urgent/emergency coronary angiography.\n\n      The optimal medical treatment for preventing the occurrence of contrast induced - acute\n      kidney injury is still controversial.\n\n      Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that\n      has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary\n      studies.\n\n      Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI\n      already shown to be useful for earlier diagnosis of contrast induced nephropathy.\n\n      The primary objective of this study is to to test the hypothesis that fenoldopam, in\n      addition to standard treatment, reduce the occurrence of contrast induced - acute kidney\n      injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary\n      angiography and/or percutaneous coronary intervention."
        }, 
        "brief_title": "Fenoldopam for Prevention of Acute Kidney Injury", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Acute Kidney Injury", 
                "Acute Coronary Syndrome", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury\n      (AKI) when they undergo urgent/emergency coronary angiography.\n\n      The optimal medical treatment for preventing the occurrence of contrast induced - acute\n      kidney injury is still controversial.\n\n      Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that\n      has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary\n      studies.\n\n      Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI\n      already shown to be useful for earlier diagnosis of contrast induced nephropathy.\n\n      The primary objective of this study is to to test the hypothesis that fenoldopam, in\n      addition to standard treatment, reduce the occurrence of contrast induced - acute kidney\n      injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary\n      angiography and/or percutaneous coronary intervention.\n\n      Patients will be randomized to standard  i.v. 1 ml/kg/h saline infusion (Gr. A, N= 50) or to\n      a combination of  i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08\n      mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.\n\n      Primary End-points\n\n      \u2022 Incidence of contrast induced acute kidney injury\n\n      Secondary End-points\n\n      \u2022 Post-angiographic 48-h absolute increase in creatinine, absolute increase in estimated\n      glomerular filtration rate, and Neutrophil gelatinase-associated lipocalin (NGAL) value"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Indication to urgent/emergency coronary angiography\n\n          -  Normal renal function (eGFR> 60 ml/min/1.73 m2)\n\n          -  Moderate or high Mehran's risk score for CIN (>11).\n\n          -  Able to understand and willing to sign the informed CF\n\n        Exclusion Criteria:\n\n        \u2022 Women of child bearing potential patients must demonstrate a negative pregnancy test\n        performed within 24 hours before CT"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690832", 
            "org_study_id": "595/2012/D"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "standard saline infusion", 
                    "fenoldopam infusion"
                ], 
                "description": "i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure", 
                "intervention_name": "standard saline infusion", 
                "intervention_type": "Drug", 
                "other_name": "saline infusion"
            }, 
            {
                "arm_group_label": "fenoldopam infusion", 
                "description": "combination of  i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure", 
                "intervention_name": "fenoldopam infusion", 
                "intervention_type": "Drug", 
                "other_name": "fenoldopam administration (0.08 mcg/Kg/min)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fenoldopam"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Contrast induced acute kidney injury", 
        "lastchanged_date": "September 19, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "state": "Lazio", 
                    "zip": "00166"
                }, 
                "name": "Sapienza University"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial", 
        "overall_official": {
            "affiliation": "Sapienza University", 
            "last_name": "Francesco Pelliccia, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of contrast induced acute kidney injury at 48 hour post-procedural control", 
            "measure": "Contrast induced acute kidney injury", 
            "safety_issue": "No", 
            "time_frame": "48 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690832"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Roma La Sapienza", 
            "investigator_full_name": "Francesco Pelliccia", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Post-angiographic 48-h absolute increase in creatinine, absolute increase in estimated glomerular filtration rate, and Neutrophil gelatinase-associated lipocalin (NGAL) value", 
            "measure": "Markers of kidney injury", 
            "safety_issue": "No", 
            "time_frame": "48 hour"
        }, 
        "source": "University of Roma La Sapienza", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Roma La Sapienza", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}